No higher resolution available.
This file is from a shared repository and may be used by other projects.
The description on its file description page there is shown below.
License
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
- &
Attribution 4.0 International (CC BY 4.0)
Summary
Author:Yoshiko Iwai, Junzo Hamanishi,Kenji Chamoto, and Tasuku Honjo,Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health Japan,Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University(Openi/National Library of medicine)Source:https://openi.nlm.nih.gov/detailedresult?img=PMC5381059_12929_2017_329_Fig2_HTML&query=Atezolizumab&it=xg&req=4&npos=2 Description:Fig2: History of PD-1 research. Abbreviations: FIM, first in man; approved, FDA-approved; NCT, “National Clinical Trial” registry number in ClinicalTrials.gov in the United States; FIM Pembrolizumab (P07990/MK-3475-001/KEYNOTE-001), NCT01295827; FIM Pidilizumab (CT-011), NCT00532259; FIM BMS-936559 (MDX-1105), NCT00729664; FIM Atezolizumab, NCT01693562; FIM Durvalumab (MEDI4736), NCT01693562; FIM Avelumab, NCT01772004
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment |
|---|
| current | 23:26, 20 January 2022 |  | 512 × 383 (223 KB) | Ozzie10aaaa | Author:Yoshiko Iwai, Junzo Hamanishi,Kenji Chamoto, and Tasuku Honjo,Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health Japan,Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University(Openi/National Library of medicine)Source:https://openi.nlm.nih.gov/detailedresult?img=PMC5381059_12929_2017_329_Fig2_HTML&query=Atezoli... |
File usage
The following page uses this file:
